purchase customization

1 Study Coverage
1.1 Multiple Sclerosis (MS) Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Multiple Sclerosis (MS) Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Copaxone (Glatiramer Acetate, Copolymer 1)
1.2.3 Novantrone (Mitoxantrone)
1.2.4 Gilenya (Fingolimod, Fty720)
1.2.5 Aubagio (Teriflunomide)
1.2.6 Tecfidera (Dimethyl Fumarate)
1.2.7 Firategrast (Sb683699, T-0047)
1.2.8 Siponimod (Baf312)
1.2.9 Others
1.3 Market by Application
1.3.1 Global Multiple Sclerosis (MS) Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 RRMS
1.3.3 SPMS
1.3.4 PPMS
1.3.5 PRMS
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Multiple Sclerosis (MS) Drugs Sales Estimates and Forecasts 2017-2028
2.2 Global Multiple Sclerosis (MS) Drugs Revenue Estimates and Forecasts 2017-2028
2.3 Global Multiple Sclerosis (MS) Drugs Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Multiple Sclerosis (MS) Drugs Sales by Region
2.4.1 Global Multiple Sclerosis (MS) Drugs Sales by Region (2017-2022)
2.4.2 Global Sales Multiple Sclerosis (MS) Drugs by Region (2023-2028)
2.5 Global Multiple Sclerosis (MS) Drugs Revenue by Region
2.5.1 Global Multiple Sclerosis (MS) Drugs Revenue by Region (2017-2022)
2.5.2 Global Multiple Sclerosis (MS) Drugs Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Multiple Sclerosis (MS) Drugs Sales by Manufacturers
3.1.1 Global Top Multiple Sclerosis (MS) Drugs Manufacturers by Sales (2017-2022)
3.1.2 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Multiple Sclerosis (MS) Drugs in 2021
3.2 Global Multiple Sclerosis (MS) Drugs Revenue by Manufacturers
3.2.1 Global Multiple Sclerosis (MS) Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Multiple Sclerosis (MS) Drugs Revenue in 2021
3.3 Global Multiple Sclerosis (MS) Drugs Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Multiple Sclerosis (MS) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Multiple Sclerosis (MS) Drugs Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Multiple Sclerosis (MS) Drugs Sales by Type
4.1.1 Global Multiple Sclerosis (MS) Drugs Historical Sales by Type (2017-2022)
4.1.2 Global Multiple Sclerosis (MS) Drugs Forecasted Sales by Type (2023-2028)
4.1.3 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2017-2028)
4.2 Global Multiple Sclerosis (MS) Drugs Revenue by Type
4.2.1 Global Multiple Sclerosis (MS) Drugs Historical Revenue by Type (2017-2022)
4.2.2 Global Multiple Sclerosis (MS) Drugs Forecasted Revenue by Type (2023-2028)
4.2.3 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2017-2028)
4.3 Global Multiple Sclerosis (MS) Drugs Price by Type
4.3.1 Global Multiple Sclerosis (MS) Drugs Price by Type (2017-2022)
4.3.2 Global Multiple Sclerosis (MS) Drugs Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Multiple Sclerosis (MS) Drugs Sales by Application
5.1.1 Global Multiple Sclerosis (MS) Drugs Historical Sales by Application (2017-2022)
5.1.2 Global Multiple Sclerosis (MS) Drugs Forecasted Sales by Application (2023-2028)
5.1.3 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2017-2028)
5.2 Global Multiple Sclerosis (MS) Drugs Revenue by Application
5.2.1 Global Multiple Sclerosis (MS) Drugs Historical Revenue by Application (2017-2022)
5.2.2 Global Multiple Sclerosis (MS) Drugs Forecasted Revenue by Application (2023-2028)
5.2.3 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2017-2028)
5.3 Global Multiple Sclerosis (MS) Drugs Price by Application
5.3.1 Global Multiple Sclerosis (MS) Drugs Price by Application (2017-2022)
5.3.2 Global Multiple Sclerosis (MS) Drugs Price Forecast by Application (2023-2028)
6 North America
6.1 North America Multiple Sclerosis (MS) Drugs Market Size by Type
6.1.1 North America Multiple Sclerosis (MS) Drugs Sales by Type (2017-2028)
6.1.2 North America Multiple Sclerosis (MS) Drugs Revenue by Type (2017-2028)
6.2 North America Multiple Sclerosis (MS) Drugs Market Size by Application
6.2.1 North America Multiple Sclerosis (MS) Drugs Sales by Application (2017-2028)
6.2.2 North America Multiple Sclerosis (MS) Drugs Revenue by Application (2017-2028)
6.3 North America Multiple Sclerosis (MS) Drugs Market Size by Country
6.3.1 North America Multiple Sclerosis (MS) Drugs Sales by Country (2017-2028)
6.3.2 North America Multiple Sclerosis (MS) Drugs Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Multiple Sclerosis (MS) Drugs Market Size by Type
7.1.1 Europe Multiple Sclerosis (MS) Drugs Sales by Type (2017-2028)
7.1.2 Europe Multiple Sclerosis (MS) Drugs Revenue by Type (2017-2028)
7.2 Europe Multiple Sclerosis (MS) Drugs Market Size by Application
7.2.1 Europe Multiple Sclerosis (MS) Drugs Sales by Application (2017-2028)
7.2.2 Europe Multiple Sclerosis (MS) Drugs Revenue by Application (2017-2028)
7.3 Europe Multiple Sclerosis (MS) Drugs Market Size by Country
7.3.1 Europe Multiple Sclerosis (MS) Drugs Sales by Country (2017-2028)
7.3.2 Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Multiple Sclerosis (MS) Drugs Market Size by Type
8.1.1 Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Type (2017-2028)
8.1.2 Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Type (2017-2028)
8.2 Asia Pacific Multiple Sclerosis (MS) Drugs Market Size by Application
8.2.1 Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Application (2017-2028)
8.2.2 Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Application (2017-2028)
8.3 Asia Pacific Multiple Sclerosis (MS) Drugs Market Size by Region
8.3.1 Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Region (2017-2028)
8.3.2 Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Multiple Sclerosis (MS) Drugs Market Size by Type
9.1.1 Latin America Multiple Sclerosis (MS) Drugs Sales by Type (2017-2028)
9.1.2 Latin America Multiple Sclerosis (MS) Drugs Revenue by Type (2017-2028)
9.2 Latin America Multiple Sclerosis (MS) Drugs Market Size by Application
9.2.1 Latin America Multiple Sclerosis (MS) Drugs Sales by Application (2017-2028)
9.2.2 Latin America Multiple Sclerosis (MS) Drugs Revenue by Application (2017-2028)
9.3 Latin America Multiple Sclerosis (MS) Drugs Market Size by Country
9.3.1 Latin America Multiple Sclerosis (MS) Drugs Sales by Country (2017-2028)
9.3.2 Latin America Multiple Sclerosis (MS) Drugs Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size by Type
10.1.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Type (2017-2028)
10.1.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Type (2017-2028)
10.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size by Application
10.2.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Application (2017-2028)
10.2.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Application (2017-2028)
10.3 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size by Country
10.3.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2017-2028)
10.3.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Bayer AG
11.1.1 Bayer AG Corporation Information
11.1.2 Bayer AG Overview
11.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Bayer AG Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bayer AG Recent Developments
11.2 Bayhill Therapeutics
11.2.1 Bayhill Therapeutics Corporation Information
11.2.2 Bayhill Therapeutics Overview
11.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bayhill Therapeutics Recent Developments
11.3 Biogen Idec
11.3.1 Biogen Idec Corporation Information
11.3.2 Biogen Idec Overview
11.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Biogen Idec Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Biogen Idec Recent Developments
11.4 Cinnagen
11.4.1 Cinnagen Corporation Information
11.4.2 Cinnagen Overview
11.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Cinnagen Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Cinnagen Recent Developments
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Corporation Information
11.5.2 Daiichi Sankyo Overview
11.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Daiichi Sankyo Recent Developments
11.6 Eli Lilly
11.6.1 Eli Lilly Corporation Information
11.6.2 Eli Lilly Overview
11.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Eli Lilly Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Eli Lilly Recent Developments
11.7 Fast Forward Llc
11.7.1 Fast Forward Llc Corporation Information
11.7.2 Fast Forward Llc Overview
11.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Fast Forward Llc Recent Developments
11.8 Antisense Therapeutics
11.8.1 Antisense Therapeutics Corporation Information
11.8.2 Antisense Therapeutics Overview
11.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Antisense Therapeutics Recent Developments
11.9 Apitope
11.9.1 Apitope Corporation Information
11.9.2 Apitope Overview
11.9.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Apitope Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Apitope Recent Developments
11.10 Five Prime Therapeutics
11.10.1 Five Prime Therapeutics Corporation Information
11.10.2 Five Prime Therapeutics Overview
11.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Five Prime Therapeutics Recent Developments
11.11 Genmab
11.11.1 Genmab Corporation Information
11.11.2 Genmab Overview
11.11.3 Genmab Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Genmab Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Genmab Recent Developments
11.12 Artielle Immunotherapeutics
11.12.1 Artielle Immunotherapeutics Corporation Information
11.12.2 Artielle Immunotherapeutics Overview
11.12.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Artielle Immunotherapeutics Recent Developments
11.13 Genzyme
11.13.1 Genzyme Corporation Information
11.13.2 Genzyme Overview
11.13.3 Genzyme Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Genzyme Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Genzyme Recent Developments
11.14 Glaxosmithkline
11.14.1 Glaxosmithkline Corporation Information
11.14.2 Glaxosmithkline Overview
11.14.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Glaxosmithkline Recent Developments
11.15 Gw Pharmaceuticals
11.15.1 Gw Pharmaceuticals Corporation Information
11.15.2 Gw Pharmaceuticals Overview
11.15.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Gw Pharmaceuticals Recent Developments
11.16 Innate Immunotherapeutics
11.16.1 Innate Immunotherapeutics Corporation Information
11.16.2 Innate Immunotherapeutics Overview
11.16.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Innate Immunotherapeutics Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Multiple Sclerosis (MS) Drugs Industry Chain Analysis
12.2 Multiple Sclerosis (MS) Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Multiple Sclerosis (MS) Drugs Production Mode & Process
12.4 Multiple Sclerosis (MS) Drugs Sales and Marketing
12.4.1 Multiple Sclerosis (MS) Drugs Sales Channels
12.4.2 Multiple Sclerosis (MS) Drugs Distributors
12.5 Multiple Sclerosis (MS) Drugs Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Multiple Sclerosis (MS) Drugs Industry Trends
13.2 Multiple Sclerosis (MS) Drugs Market Drivers
13.3 Multiple Sclerosis (MS) Drugs Market Challenges
13.4 Multiple Sclerosis (MS) Drugs Market Restraints
14 Key Findings in The Global Multiple Sclerosis (MS) Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer